The CLEC1A antibody targets C-type lectin domain family 1 member A (CLEC1A), a transmembrane protein belonging to the C-type lectin receptor (CLR) family. CLEC1A, also known as CLEC-1. is encoded by the CLEC1A gene located on human chromosome 12p13.2. Structurally, it contains a single extracellular C-type lectin-like domain, a transmembrane region, and a cytoplasmic tail lacking canonical signaling motifs like immunoreceptor tyrosine-based activation motifs (ITAMs) or inhibitory motifs (ITIMs). It is primarily expressed on dendritic cells, monocytes, and macrophages, suggesting roles in immune regulation. CLEC1A is proposed to function as a pattern recognition receptor, though its endogenous ligands remain unclear. Some studies indicate it may interact with damaged or necrotic cells, facilitating immune surveillance. Research highlights its involvement in modulating T-cell responses, promoting immune tolerance, and influencing anti-viral or anti-tumor immunity. Antibodies against CLEC1A are used to investigate its expression, ligand interactions, and signaling pathways. Despite its potential in therapeutic targeting (e.g., cancer immunotherapy), the exact mechanisms and physiological relevance of CLEC1A in disease contexts require further exploration. Current challenges include clarifying ligand specificity and downstream signaling partners to unlock its clinical applications.